Search for content, post, videos

InDex, Almirall S.A End Agreement

InDex Pharmaceuticals terminated a license agreement with Almirall S.A. involving the drug candidate Kappaproct® for the treatment of ulcerative colitis. The agreement had given Almirall licensed exclusive rights to Kappaproct® for the European market. Now InDex regains all worldwide development a
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.